DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay
SAN DIEGO--(BUSINESS WIRE)-- DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that it will ...
LA JOLLA, Calif.--(BUSINESS WIRE)-- DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced ...
The company's skin diagnostic test, dubbed DMT, has an uncanny ability to pick up the highly prevalent skin cancer, melanoma. Commercialization has been modest due to various launch barriers.
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive ...
Traditional analog test techniques and specifications, which are based on sine-wave testing, don't reflect the true performance of devices that process the discrete-multitone waveform. A unique ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback